RecruitingPhase 2

Tranexamic Acid in Nasal Mohs Reconstruction

United States100 participantsStarted 2024-03-19

Plain-language summary

This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults at least 18 years of age undergoing local flap reconstruction (bilobe flap, note flap dorsal nasal flap, advancement flap) of a nasal defect following Mohs micrographic surgery. Reconstructive procedures will be performed by Drs. Yang or Patel in the division of Facial Plastic Surgery in the Department of Otolaryngology, Head and Neck Surgery at Vanderbilt University Medical Center.
✓. No other facial plastic procedure or sinus surgery performed simultaneously.

Exclusion criteria

✕. Known allergy to TXA
✕. Intracranial bleeding
✕. Known defective color vision
✕. History of venous or arterial thromboembolism
✕. History of coagulation disorder
✕. Active thromboembolic disease
✕. Severe renal impairment (diagnosis of chronic kidney disease)
✕. History of acute myocardial infarction

What they're measuring

Surgical site swelling and bruising (surgeon)

Timeframe: One week

Surgical site swelling and bruising (patient)

Timeframe: One week

Intraoperative bleeding

Timeframe: Intraoperative

Intraoperative bleeding

Timeframe: Intraoperative

Trial details

NCT IDNCT06057675

SponsorVanderbilt University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06

Contact for this trial

Connie Ma, MD

2815366877 connie.ma@vumc.org

View on ClinicalTrials.gov More Postoperative Bleeding trials